Nurix Q3 FY2025 net loss $86.4M ($1.03/share); cash $428.8M; bexobrutideg pivotal trials on track

Nurix Therapeutics, Inc.

2025-Q3 EPS reported -$2.22 revenue$70,403,000

Revenue $7.9M vs $12.6M YoY; net loss $86.4M ($1.03/sh) vs $49.0M ($0.67/sh) YoY.
Cash and securities $428.8M (down from $609.6M at Nov 2024); R&D spend $86.1M, up 55% YoY.
Bexobrutideg ORR 80.9% in CLL (n=47) and 84.2% in WM (n=19); pivotal trials planned H2 2025.
Preclinical data for GS-6791 (IRAK4 degrader with Gilead) presented at EADV; IND-enabling STAT6 degrader with Sanofi.
Collaboration revenue declined as Sanofi initial research term ended; partially offset by Pfizer milestone completion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.